Form 4: Dare Bioscience Director, Susan L. Kelley, Acquires 40,000 Stock Options

Director Susan L. Kelley acquired 40,000 stock options in Dare Bioscience, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Susan L. Kelley, a director of Dare Bioscience, Inc., acquired 40,000 stock options.
• The options have an exercise price of $0.43.
• The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options will become exercisable in full upon a change in control of the issuer.
• The expiration date for the options is June 5, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports the acquisition of stock options by a director, which is a routine event. It doesn't inherently indicate positive or negative sentiment, but the director's confidence in the company could be interpreted as slightly positive.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. It is common for directors and officers to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates